

# Special Issue

## Real Life Experience of the COVID-19 Vaccine: What Do You Need to Know?

### Message from the Guest Editor

The quick development of several types of COVID-19 vaccines, based on mRNA technology and viral vectors, should be considered the biggest goal the scientific community has reached in recent decades. Once the evidence of efficacy and safety was clearly demonstrated in clinical trials, the most important challenge was finding evidence of effectiveness in a wider population. This is what real life studies intended to demonstrate during the mass vaccination campaign. Now, scientific community shares an important social responsibility by analyzing data and communicating the evidence in order to sustain equity in the vaccination campaign. To achieve a more extensive understanding of recent scientific knowledge and current trends in the SARS-CoV-2 vaccines, this Special Issue is focused on the recent scientific, strategies and results in real life. Based on your extensive knowledge and experience, we invite you to contribute with an original report, original observation or review, to highlight:

- strategies of vaccination;
- safety, immunogenicity and efficacy of SARS-CoV-2 vaccines;
- effectiveness in real-world;
- advances in vaccines development.

---

### Guest Editor

Prof. Dr. Vincenzo Baldo

Department of Cardiologic, Vascular and Thoracic Sciences, and Public Health, University of Padova, 35128 Padova, Italy

---

### Deadline for manuscript submissions

closed (31 January 2024)



# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4

CiteScore 9.9

Indexed in PubMed



[mdpi.com/si/106425](https://mdpi.com/si/106425)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
vaccines@mdpi.com

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

an Open Access Journal  
by MDPI

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](http://mdpi.com/journal/vaccines)

## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).

